

# **VALIDATION OF EUROSCOR II IN EGYPTIAN CABG PATIENT**

---

## **Thesis**

Submitted in Complete Fulfillment of  
The Doctorate Degree (PhD) in

**Cardiothoracic Surgery**

By

***Khaled Mortada Mohammed Elsayed***

*Assistant lecturer*

Under Supervision of

**PROF. DR. Yahia Balbaa Anwar Balbaa**

*Professor of Cardiothoracic Surgery,  
Faculty of Medicine, Cairo University*

**PROF.DR.Mohamed Ibrahim Ahmad Sewielam**

*Professor of Cardiothoracic Surgery  
Faculty of Medicine, Cairo University*

**LECTURER .DR. Fouad Mohammed Said Rassekh**

*Assistant Professor of Cardiothoracic Surgery  
Faculty of Medicine, Cairo University*

**Faculty of Medicine  
Cairo University  
2015**

## ACKNOWLEDGEMENT

*First and foremost, thanks are due to **ALLAH** the most gracious and merciful, to whom I attribute my success in achieving any work in my life.*

*Second, to **my father, mother and wife** who spent their lives pushing me forward.*

*I would like to express my sincere gratitude and deepest appreciation to my **Professor Dr.YahiaBalbaa**, Professor of Cardiothoracic Surgery, Faculty of Medicine, Cairo University, for his continuous encouragement and precious guidance throughout the preparation of this work.*

*I am deeply grateful to **Professor Dr. Mohamed Sewielam**, Professor of Cardiothoracic Surgery, Faculty of Medicine, Cairo University, for his help and comments that enlightened my way through out this work.*

*I would like also to thank **Professor Dr.Fouad Rassekh**, Assistant Professor of Cardiothoracic Surgery, Faculty of Medicine, Cairo University, for his patience, suggestions and cooperation to achieve this work.*

*Finally, I wish to express my appreciation to all staff of Cardiothoracic Surgery, Faculty of Medicine, Cairo University, who shared their thoughts and comments with me to achieve this work.*

Khaled Mortada

# CONTENTS

	Page
▪ Abstract .....	1
▪ List of Tables.....	2
▪ List of Figures.....	4
▪ Introduction .....	5
▪ Review of Literature .....	7
- Introduction to CABG .....	7
- Cardiac Surgery Risk Stratification Models .....	13
- Parsonnet (Initial) score.....	16
- Tuman score .....	18
- Cleveland score.....	20
- Tremblay score.....	23
- Veterans Affairs score.....	25
- French score .....	27
- Ontario score .....	29
- Cabdeal score .....	31
- Magovern score .....	34
- Parsonnet(modified)score.....	38
- Pons score .....	41
- UK National score.....	44
- Northern New England score .....	45
- Toronto score .....	46
- Toronto (modified) score.....	47
- New York score.....	48

- Amphia score .....	50
- STS score.....	54
- SYNTAX score.....	57
- Euroscore .....	58
- EuroscoreII.....	64

▪ <b>Patients and Methods.....</b>	<b>77</b>
▪ <b>Statistical analysis.....</b>	<b>84</b>
▪ <b>Results.....</b>	<b>86</b>
▪ <b>Discussion.....</b>	<b>98</b>
▪ <b>Summary &amp; Conclusion.....</b>	<b>108</b>
▪ <b>References .....</b>	<b>109</b>
▪ <b>Arabic.....</b>	<b>124</b>



## Abstract

---

The aim of the present study is to validate the applicability of EuroSCOREII as a preoperative predictive scoring system of mortality for Egyptian patients undergoing coronary artery bypass grafting surgery.

A randomized prospective study was done including Patients with I.H.D. undergoing isolated CABG surgery performed by EL KasrELAiny staff.

Total patients number was 545 patients from which 2 patients did not had the operation and 25 patients were excluded due to associated valve lesion so 518 patients were included from which 15 patients died.

According to data of patients who shared in this study and after calculation of EuroSCORE II for each patient, calculation of the mean EuroSCOREII was 1.1325%, 15 cases of postoperative mortality were recorded presenting 2.89% of the whole study.

The area under receiver operating characteristic curve (AUC) was 0.675 which means that EuroSCORE II isn't predictive of mortality in Egyptian CABG patients.

### **Key words:**

EuroSCOREIICABGmortalityEgyptian ROC curve

500 patientsvalidation EL KasrELAiny

# List of tables

---

Number	Table title	Page
1	Synopsis of original data of multiple risk score algorithms	14
2	Description of the initial parsonnet's score	17
3	Short Manual Model With Seven Risk Factors	33
4	Description of the risk factors of modified parsonnet's score	38
5	Risk factor for STS score	56
6	National patient and center distribution	61
7	Participating countries (43) and number of units (154)	65
8	Risk factors in EuroSCORE, EuroSCORE II	74
9	Euro SCORE II for gender distribution for the patients	87
10	Euro SCORE II for chronic pulmonary disease distribution for the patients	87
11	Euro SCORE II values for ECA distribution in patients of the study.	88
12	Euro SCORE II values for neurological dysfunction distribution in patients of the study.	88
13	Euro SCORE II values for renal function in patients of the study.	89
14	Euro SCORE II values for critical preoperative state incidence in patients of the study. .	90
15	Euro SCORE II values for diabetic patients distribution in patients of the study.	90
16	Euro SCORE II values for unstable angina incidence.	91

17	Distribution of NYHA functional class of chest pain in patients of the studied group	92
18	Euro SCORE II values for NYHA classes distribution of patients of the study	93
19	Euro SCORE II values for LV function in patients of the study.	94
20	Euro SCORE II values for recent MI incidence in patients of the study.	94
21	Euro SCORE II values for pulmonary hypertension in patients of the study.	95
22	Euroscore II values for emergency incidence in patients of the study. .	95
23	Euro SCORE II values for Wight of the intervention in patients of the study. .	96



# LIST OF FIGURES

---

Number	Figure title	Page
1	Differences of specificity and sensitivity between additive and logistic EuroSCORE.	60
2	Euro SCORE calculator	63
3	Areas under the ROC curve for the previous additive and logistic models applied to current data, and the new logistic EuroSCORE II model	67
4	Risk factor calculator for Euro SCORE II	76
5	The distribution of gender patient among the studied group	86
6	The distribution of chronic pulmonary disease patients among the studied group.	87
7	The distribution of patients with Diabetes Mellitus (DM) among patients of the studied group.	87
8	The distribution of patient with IDDM among patients of the studied group	88
9	The distribution of patients among the studied group according to functional class of chest pain.	90
10	ROC curve	94

# Introduction

---

Risk prediction in current cardiac surgical practice plays an important role in surgical decision-making preoperative patient education& consent, it also enable comparison between centers.

Despite technological advancements, open-heart operations still carry a risk of mortality and morbidity.

Preoperative risk scores are an essential tool for risk assessment, cost benefit analysis, the study of therapy trends and to aid in the selection of patients for cardiac surgery, Various score systems have been developed to predict mortality after adult heart surgery. (Roques F, Nashef SAM et al., 1999).

Operative mortality is also increasingly used as an indicator of the quality of cardiac surgery. (Dubois RW, Rogers WH et al., 1987)

Although all of these score systems are based on patient derived data, such as age, gender, comorbidity, and so forth, there are considerable differences between scores with regard to their design and validity.

As quality control and cost-benefit analysis have gained new relevance with recent developments in the health care system, selection of appropriate score systems for the evaluation of hospital performance has become an important issue.

With no knowledge of the current risk profile of Egyptian cardiac surgical patients, crude mortality rate in a center was once used as a risk indicator in Egypt, although it is usually not related to preoperative risk factors.

The European system for cardiac operative risk evaluation (Euroscore II) aiming to predict 30-day mortality of the European cardiac surgical patients is now the most widely used risk prediction algorithm in Egypt.

## Introduction

Owing to its validation in European, North America and Japanese populations, however validation of Euroscore II model has never been tested in Egypt.

Hence there is a doubt as to whether or not the European model for risk prediction was appropriate in Egypt.

Over the last decade patients undergoing coronary artery bypass graft (CABG) have been increasing rapidly in Egypt due to increasing number of I.H.D. we have therefore to analyze the prediction ability of Euroscore II on the patients undergoing CABG in Egypt aiming to assess the applicability of the Euroscore II in egyptian patient undergoing CABG.

Hence the specific questionis to be addressed primarily:

**Is the EuroscoreII an accurate operative risk predictor for CABG in Egypt?**

# Introduction to CABG

---

## Historical background

By following the history of myocardial revascularization worldwide, it is clearly visible that it passed progressive sequential steps. In 1962, a cardiac surgeon by the name of Sabiston conducted the first unsuccessful saphenous vein graft from the ascending aorta to the distal right coronary artery and the patient died 3 days later. The technique was then pioneered by Argentinian René Favaloro and others at the Cleveland Clinic in the late 1960s. The next major development was in 1970, when the internal mammary artery was used as a bypass conduit to the coronary arteries. By the mid 1970s, many centers in the United States, Australia, and Europe were performing CABG with low peri-procedural mortality, and a high rate of pain relief (**PollickC 1993, Keenan and Chou 1998**).The first minimally invasive cardiac surgery/coronary artery bypass grafting was performed on January 21, 2005, at what was then The Heart Institute of Staten Island by a highly trained team led by Dr. Joseph McGinn.

Between (1972) and (1984) several randomized trials compared medical and surgical therapy for the treatment of atherosclerotic CAD. The two major trials, the Coronary Artery Surgery Study (CASS),(**Eagle et al., 2004**) and the European Coronary Surgery Study (ECSS)(**Hawkes et al., 2006**)demonstrate the greatest survival benefit of revascularization to be among those patients at highest risk.

## **Timing of operation:**

Preoperative hemodynamic instability and/or unstable angina often prompt urgent or emergent surgery. In stable patients, factors to be consider when planning the timing of surgery include the time since cardiac catheterization, the administration of nephrotoxic medications or agents, and the baseline creatinine due to the risk of postoperative renal dysfunction (**Duddakula K et al., 2007**).

Caution should be taken in the stable patient with an acute myocardial infarction in the setting of poor left ventricular function. Allowing recovery from the acute event prior to surgery may decrease morbidity and mortality (**Lee DC et al., 2007**).

Prohibitory systemic illnesses may also indicate a need for further work up or delay in elective surgery as well as additional consultations. Consideration should also be made for a delay in the stable patient when preoperative antithrombotic therapy has been administered due to the increased risk of perioperative bleeding.

## **Outcome:**

### **Mortality :**

Worldwide interest has increased over the last 10 years in evaluating hospital performance through the assessment of actual results of patients care. Outcome based quality assessment in health care has been a growing interest for policymakers, administrators and clinicians. The most significant examples of outcomes studies are mainly related to cardiac surgery, particularly to coronary artery by-pass graft (CABG) and come from the United States, Canada and the United Kingdom (**Ferguson TB, Hammil BG, Peterson ED et al ., 2002**).

These studies allowed the public to have systematic access to health performance results of each hospital and documented wide variations between surgeons, hospitals and regions in post-CABG mortality that persist despite statistical adjustment for differences in patients case-mix.

In fact, in order to control for confounding, when centres outcomes are compared, it is mandatory to take into account and control the potential effect of centers being heterogeneous with regard to variables which describe the severity of the disease for which the patient is being treated and his individual preoperative risk.( Ugolini C, Nobilio L et al., 2004).

In Egypt there is no surveillance system aimed to regularly assess the outcomes of hospital care. A few isolated initiatives were made during the last decade, but they were at the regional level and involved only a limited number of hospitals .

Early in hospital mortality from primary coronary artery bypass surgery has seen a steady decline from the 1970s into the 1990s. Recently, however, the patient population referred for coronary artery bypass has become increasingly complex; hence the decline has plateaued in recent years.

Older patient, more advanced and diffuse coronary artery disease, worsening left ventricular function, failure of multiple previous percutaneous manipulation, more serious comorbidities, and a greater frequency of reoperation have contributed to an increase in perioperative risk. Therefore only risk adjusted outcome data can be truly informative.

Currently, the overall operative mortality rate for CABG is about 3 percent, elective primary CABG carries a mortality rate of 1.2 percent, according to the database of the Society of Thoracic Surgeons.

**A) Possible complications of CABG surgery (morbidity):**

- **Graft failure or coronary spasm:**

Graft patency may be enhanced by the administration of antiplatelet agents including aspirin and/or Plavix that are reinstituted when safe, the use of inotropes or mechanical support to maintain an adequate cardiac output, and the use of calcium channel blockers or nitrates for the prevention of arterial graft spasm (Maniar HS et al., 2002).

- **Infection:**

The STS 2008 Report observed rate of deep sternal wound infection was 0.4%(risk adjusted 0.3%) in patients undergoing isolated CABG. Perioperative intravenous antibiotics are administered prior to incision and continued for 48 hours or less postoperatively. Additional antibiotic use should be guided by specific culture and sensitivity studies. In addition, aggressive blood sugar management (often with insulin infusion) is utilized to limit the occurrence of sternal wound infection (Gandhi GY et al., 2005, Guvener M et al., 2002 and Furnary AP et al., 2003).

- **Postoperative bleeding/early tamponade:**

Appropriate surgical hemostasis should be obtained prior to chest closure to avoid postoperative bleeding. Tamponade requires immediate operative drainage